Please login to the form below

Not currently logged in
Email:
Password:

Lundbeck reports profit fall

Danish drugs manufacturer Lundbeck has posted a 1.6 per cent fall in first-quarter net profit to DKK930m (€124.7m)

Danish drugs manufacturer Lundbeck has posted a 1.6 per cent fall in first-quarter net profit to DKK930m (€124.7m).

The company's revenue increased by 7 per cent to DKK4.1bn (€550m) in the first quarter, however, driven by a positive development of key products: antidepressant Cipralex (escitalopram), Alzheimer's treatment Ebixa (memantine) and Parkinson's treatment Azilect (rasagiline). Lundbeck said the products generated sales growth in the quarter, of 6 per cent, 12 per cent and 15 per cent respectively.

Ulf Wiinberg, chief executive, said: "It has been a good first quarter and several positive pipeline events have improved our long-term outlook."

The company still expects to make full-year sales of up to DKK15.8bn (€2.2bn). Earnings before interest and tax, depreciation and amortisation (EBITDA) is still expected to be up to DKK4.6bn (€616m).

5th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics